Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Extraosseous Ewing Sarcoma Clear all

Completed Phase 2 Interventional Results available

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

NCT00516295

View directory record Official record

Conditions: Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions: topotecan hydrochloride, vincristine sulfate, cyclophosphamide, bevacizumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 29 Years

Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Sep 1, 2014 · Synced May 21, 2026, 5:33 PM EDT

Completed Phase 2 Interventional

Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma

NCT00003667

View directory record Official record

Conditions: Sarcoma
Interventions: cyclophosphamide, dexrazoxane hydrochloride, disaccharide tripeptide glycerol dipalmitoyl, doxorubicin hydrochloride, vincristine sulfate, surgical procedure, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years to 60 Years

Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Source: ClinicalTrials.gov public record

Updated Jun 24, 2013 · Synced May 21, 2026, 5:33 PM EDT

Completed Early Phase 1 Interventional

18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma

NCT01825902

View directory record Official record

Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: fluorine F 18 fluorothymidine, fludeoxyglucose F 18, positron emission tomography, diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis; Drug · Radiation · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 7 Years and older

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Source: ClinicalTrials.gov public record

Updated Nov 19, 2017 · Synced May 21, 2026, 5:33 PM EDT

Withdrawn Not applicable Interventional

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

NCT01795430

View directory record Official record

Conditions: Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation; Drug · Radiation · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 6 Months to 40 Years

Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Duarte, California

Source: ClinicalTrials.gov public record

Updated Jan 8, 2015 · Synced May 21, 2026, 5:33 PM EDT

Completed Phase 2 Interventional Results available

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

NCT01222767

View directory record Official record

Conditions: Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
Interventions: Zalypsis; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 16 Years and older

Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Santa Monica, California • Memphis, Tennessee • Seattle, Washington

Source: ClinicalTrials.gov public record

Updated Oct 28, 2021 · Synced May 21, 2026, 5:33 PM EDT

Completed Phase 2 Interventional

Chemotherapy in Treating Children With Recurrent or Refractory Sarcomas

NCT00003745

View directory record Official record

Conditions: Sarcoma
Interventions: topotecan hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years

Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Source: ClinicalTrials.gov public record

Updated Feb 4, 2013 · Synced May 21, 2026, 5:33 PM EDT

Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

NCT01231906

View directory record Official record

Conditions: Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Interventions: Cyclophosphamide, Dexrazoxane, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Vincristine Sulfate; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years

Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 215
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 149 more

Source: ClinicalTrials.gov public record

Updated Jan 22, 2026 · Synced May 21, 2026, 5:33 PM EDT

Terminated Phase 3 Interventional Results available

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

NCT01132547

View directory record Official record

Conditions: Cancer
Interventions: cyproheptadine hydrochloride, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 2 Years to 21 Years

Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 14
States / cities: Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more

Source: ClinicalTrials.gov public record

Updated Jul 1, 2015 · Synced May 21, 2026, 5:33 PM EDT